Subscribe to RSS
DOI: 10.1055/s-0029-1186271
© Georg Thieme Verlag KG Stuttgart · New York
Efficacy of the Non-Adenosine Analogue A1 Adenosine Receptor Agonist (BR-4935) on Cardiovascular Function after Cardiopulmonary Bypass
Publication History
received February 1, 2009
Publication Date:
23 March 2010 (online)
Abstract
Background: We tested the hypothesis that pharmacological preconditioning with a newly developed, potent non-adenosine analogue A1AdoR agonist (BR-4935) improves biventricular cardiac and endothelial function after cardiopulmonary bypass. Methods: Twelve anesthetized dogs underwent cardiopulmonary bypass. Dogs were divided into two groups: group 1 (n = 6) received saline vehicle, group 2 (n = 6) received BR-4935 before cardiopulmonary bypass. Biventricular hemodynamic variables were measured using a combined pressure-volume conductance catheter. Coronary blood flow, ATP content, malondialdehyde and myeloperoxidase levels and vasodilatative responses to acetylcholine and sodium nitroprusside were also determined. Results: Administration of the A1AdoR agonist led to a significantly better recovery of left and right ventricular systolic function after 60 minutes of reperfusion. Although the vasodilatative response to sodium nitroprusside was similar in both groups, acetylcholine resulted in a significantly greater increase in coronary blood flow in the BR-4935 group. In addition, the ATP content was significantly higher in the same group. Furthermore, malondialdehyde and myeloperoxidase levels significantly decreased in the A1AdoR group. Conclusion: Pharmacological preconditioning with a new, potent non-adenosine analogue A1AdoR agonist improves biventricular function recovery and endothelial function after hypothermic cardiac arrest.
Key words
myocardial protection - cardiovascular surgery - coronary bypass surgery
References
- 1 Wallace A, Lam H W, Nosé P S, Bellows W, Mangano D T. Changes in systolic and diastolic ventricular function with cold cardioplegic arrest in man. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. J Card Surg. 1994; 9 (Suppl. 3) 497-502
- 2 Forman M B, Velasco C E. Role of adenosine in the treatment of myocardial stunning. Cardiovasc Drugs Ther. 1991; 5 (5) 901-908
- 3 Ely S W, Berne R M. Protective effects of adenosine in myocardial ischemia. Circulation. 1992; 85 (3) 893-904
- 4 Shryock J C, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol. 1997; 79 (12) 2-10
- 5 Yaar R, Jones M R, Chen J F, Ravid K. Animal models for the study of adenosine receptor function. J Cell Physiol. 2005; 202 (1) 9-20
- 6 Thornton J D, Liu G S, Olsson R A, Downey J M. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation. 1992; 85 (2) 659-665
- 7 Toombs C F, McGee S, Johnston W E, Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation. 1992; 86 (3) 986-994
- 8 Lasley R D, Rhee J W, Van Wylen D G, Mentzer Jr R M. Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart. J Mol Cell Cardiol. 1990; 22 (1) 39-47
- 9 Liu G S, Thornton J, Van Winkle D M, Stanley A W, Olsson R A, Downey J M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991; 84 (1) 350-356
- 10 Van Winkle D M, Chein G L, Wolff R A, Soifer B E, Kuzume K, Davis R F. Cardioprotection provided by adenosine receptor activation is abolished by blockade of the KATP channel. Am J Physiol. 1994; 266 (2 Pt 2) H829-H839
- 11 Auchampach J A, Gross G J. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am J Physiol. 1993; 264 (5 Pt 2) H1327-H1336
- 12 Rosentreter U, Kraemer T, Shimada M et al. Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same. Patent Pub No. WO/2003/053441.
- 13 Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki L M. Apoptosis in human acute myocardial infarction. Circulation. 1997; 95 (2) 320-323
- 14 Murry C E, Jennings R B, Reimer K A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74 (5) 1124-1136
- 15 Yellon D M, Downey J M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003; 83 (4) 1113-1151
- 16 Baines C P, Cohen M V, Downey J M. Signal transduction in ischemic preconditioning: the role of kinases and mitochondrial K(ATP) channels. J Cardiovasc Electrophysiol. 1999; 10 (5) 741-754
- 17 Miura T, Liu Y, Kita H, Ogawa T, Shimamoto K. Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol. 2000; 35 (1) 238-245
- 18 Louttit J B, Hunt A A, Maxwell M P, Drew G M. The time course of cardioprotection induced by GR79236, a selective adenosine A1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig. J Cardiovasc Pharmacol. 1999; 33 (2) 285-291
- 19 Finegan B A, Lopaschuk G D, Gandhi M, Clanachan A S. Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischaemia. Br J Pharmacol. 1996; 118 (2) 355-363
- 20 Bolling S F, Bies L E, Gallagher K P, Bove E L. Enhanced myocardial protection with adenosine. Ann Thorac Surg. 1989; 47 (6) 809-815
- 21 Parker P E, Bashour F A, Downey H F, Boutros I S. Coronary reperfusion: effects of vasodilators (papaverine and adenosine). Am Heart J. 1977; 93 (1) 66-72
- 22 Cox B F, Greenland B D, Perrone M H, Merkel L A. Ischaemia/reperfusion selectively attenuates coronary vasodilatation to an adenosine A2- but not to an A1-agonist in the dog. Br J Pharmacol. 1994; 111 (4) 1233-1239
- 23 Vanden Hoek T, Becker L B, Shao Z H, Li C Q, Schumacker P T. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ Res. 2000; 86 (5) 541-548
- 24 Narayan P, Mentzer Jr R M, Lasley R D. Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes. J Mol Cell Cardiol. 2001; 33 (1) 121-129
- 25 Jordan J E, Zhao Z Q, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999; 43 (4) 860-878
-
26
Loria V, Dato I, Graziani F, Biasucci L M.
Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes.
Mediators Inflamm.
2008;
DOI: 10.1155/2008/135625
, published online March 11, 2008
- 27 Budde J M, Morris C D, Velez D A et al. Reduction of infarct size and preservation of endothelial function by multidose intravenous adenosine during extended reperfusion. J Surg Res. 2004; 116 (1) 104-115
- 28 Schmitt J P, Schröder J, Schunkert H, Birnbaum D E, Aebert H. Role of apoptosis in myocardial stunning after open heart surgery. Ann Thorac Surg. 2002; 73 (4) 1229-1235
- 29 Shalaby A, Rinne T, Järvinen O et al. Initial results of a clinical study: adenosine enhanced cardioprotection and its effect on cardiomyocytes apoptosis during coronary artery bypass grafting. Eur J Cardiothorac Surg. 2008; 33 (4) 639-644
- 30 Lee H T, LaFaro R J, Reed G E. Pretreatment of human myocardium with adenosine during open heart surgery. J Card Surg. 1995; 10 (6) 665-676
- 31 Mentzer Jr R M, Birjiniuk V, Khuri S et al. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg. 1999; 229 (5) 643-649 discussion 649-650
- 32 Cohen G, Feder-Elituv R, Iazetta J et al. Phase 2 studies of adenosine cardioplegia. Circulation. 1998; 98 (Suppl. 19) II225-II233
- 33 Teoh L K, Grant R, Hulf J A, Pugsley W B, Yellon D M. The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc Res. 2002; 53 (1) 175-180
1 These authors contributed equally to this work.
Gábor Veres, MD
Department of Cardiac Surgery
University of Heidelberg
INF 326
69120 Heidelberg
Germany
Phone: + 49 62 21 56 62 46
Fax: + 49 62 21 56 45 71
Email: gaborveres@yahoo.com